| pubmed-article:17171160 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17171160 | lifeskim:mentions | umls-concept:C0006826 | lld:lifeskim |
| pubmed-article:17171160 | lifeskim:mentions | umls-concept:C0149543 | lld:lifeskim |
| pubmed-article:17171160 | lifeskim:mentions | umls-concept:C0008838 | lld:lifeskim |
| pubmed-article:17171160 | lifeskim:mentions | umls-concept:C0574032 | lld:lifeskim |
| pubmed-article:17171160 | lifeskim:mentions | umls-concept:C0205250 | lld:lifeskim |
| pubmed-article:17171160 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:17171160 | pubmed:dateCreated | 2006-12-15 | lld:pubmed |
| pubmed-article:17171160 | pubmed:abstractText | Treatment results for malignant skull base lesions may be improved with combined modality therapy. Using a novel drug infusion technique that capitalizes on the pharmacodynamic cisplatin-neutralizing properties of thiosulfate, 14 patients (6 untreated, 8 recurrent) received cisplatin (120 to 200 mg/m(2) for 1 to 4 weeks x 2-4 cycles) as part of a multimodality treatment program. Histology included squamous cell carcinoma, 11 patients (8 upper aerodigestive tract, 3 cutaneous); sarcoma, 2 patients (malignant fibrous histiocytoma, synovial cell sarcoma); and salivary gland cancer, 1 patient. The lesions involved the lateral skull base (12 patients) and the anterior (2 patients).Dose intensities for cisplatin were between 33.3 and 200 mg/m(2)/wk. Major responses occurred in 9/14 patients (64.3%), 3 of whom had complete responses. Drug toxicity, occurring in 11 patients, was mild and there were no significant complications as a result of the infusions. Eleven patients subsequently underwent surgical resections. The mean survival time is 23.3 months. Eight patients are alive without disease, 2 alive with disease, and 4 are dead of disease.The effectiveness of this highly selective supradose cisplatin infusion technique and its low morbidity support continued investigations of its application to patients with cranial base malignancies. | lld:pubmed |
| pubmed-article:17171160 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17171160 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17171160 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17171160 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17171160 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17171160 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17171160 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17171160 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17171160 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17171160 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17171160 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17171160 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17171160 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17171160 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17171160 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17171160 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17171160 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17171160 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17171160 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17171160 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17171160 | pubmed:status | PubMed-not-MEDLINE | lld:pubmed |
| pubmed-article:17171160 | pubmed:issn | 1052-1453 | lld:pubmed |
| pubmed-article:17171160 | pubmed:author | pubmed-author:HarrisJ PJP | lld:pubmed |
| pubmed-article:17171160 | pubmed:author | pubmed-author:KerberCC | lld:pubmed |
| pubmed-article:17171160 | pubmed:author | pubmed-author:VicarioDD | lld:pubmed |
| pubmed-article:17171160 | pubmed:author | pubmed-author:RobbinsK TKT | lld:pubmed |
| pubmed-article:17171160 | pubmed:author | pubmed-author:PellitteriP... | lld:pubmed |
| pubmed-article:17171160 | pubmed:author | pubmed-author:HanchettCC | lld:pubmed |
| pubmed-article:17171160 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17171160 | pubmed:volume | 4 | lld:pubmed |
| pubmed-article:17171160 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17171160 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17171160 | pubmed:pagination | 122-6 | lld:pubmed |
| pubmed-article:17171160 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:17171160 | pubmed:articleTitle | Highly selective infusions of supradose Cisplatin for cranial base malignancies. | lld:pubmed |
| pubmed-article:17171160 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17171160 | lld:pubmed |
